CFLAR and triple-negative breast carcinoma: Sun et al. demonstrated that tetrahydrocurcumin targets TRIP13, inhibits TRIP13/USP7/c-FLIP interaction, and mediates c-FLIP ubiquitination in triple-negative breast cancer [21].